Literature DB >> 18607572

Effects of nicotine on quinpirole- and dizocilpine (MK-801)-induced sensorimotor gating impairments in rats.

Amy A Nespor1, Yousef Tizabi.   

Abstract

RATIONALE: Prepulse inhibition (PPI) of the acoustic startle response (ASR) is used as an index of sensorimotor gating to assess preattentive processes. Impairments in PPI have been observed in many neuropsychiatric disorders, especially schizophrenia. Administration of the glutamate N-methyl-D-aspartate receptor antagonist dizocilpine (MK-801) or dopamine receptor (D2/D3) agonist quinpirole (QNP) results in impairment (reduction) of PPI in rats. Nicotine, on the other hand, may have beneficial effects on attentional/cognitive functions.
OBJECTIVE: The purpose of the current set of experiments was to investigate the effects of acute and chronic nicotine on MK-801- and QNP-induced PPI impairments.
MATERIALS AND METHODS: Adult female Sprague-Dawley rats were treated acutely or chronically by various doses of nicotine alone or followed by an acute dose of MK-801 (0.15 mg/kg) or QNP (0.5 mg/kg). All drugs were administered intraperitoneally. Controls received saline in lieu of any drug, and ASR and PPI in each animal was evaluated 10 min after the last injection.
RESULTS: Both MK-801 and QNP consistently impaired PPI. Administration of nicotine acutely (0.05-0.4 mg/kg) or chronically (0.2 or 0.4 mg/kg daily for 1 week) did not have any effect of its own on ASR or PPI or on MK-801-induced PPI impairment. Acute administration of 0.2 mg/kg nicotine did not have any effect on QNP-induced reduction in PPI, whereas the higher dose of 0.4 mg/kg significantly attenuated this impairment. Chronic daily administration of either 0.2 or 0.4 mg/kg nicotine for 1 week nearly normalized the QNP-induced impairments in PPI.
CONCLUSION: The effect of nicotine on sensorimotor gating is dependent on the procedure as well as the dose of nicotine and appears to be efficacious against dopaminergic rather than glutamatergic disruption of PPI in rats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18607572     DOI: 10.1007/s00213-008-1220-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  71 in total

Review 1.  Nicotine use in schizophrenia: the self medication hypotheses.

Authors:  Veena Kumari; Peggy Postma
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

2.  Effects of the PCP analog dizocilpine on sensory gating: potential relevance to clinical subtypes of schizophrenia.

Authors:  H A al-Amin; S B Schwarzkopf
Journal:  Biol Psychiatry       Date:  1996-10-15       Impact factor: 13.382

Review 3.  Smoking and mental illness.

Authors:  S Leonard; L E Adler; K Benhammou; R Berger; C R Breese; C Drebing; J Gault; M J Lee; J Logel; A Olincy; R G Ross; K Stevens; B Sullivan; R Vianzon; D E Virnich; M Waldo; K Walton; R Freedman
Journal:  Pharmacol Biochem Behav       Date:  2001-12       Impact factor: 3.533

Review 4.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

5.  Sensitivity to the dopaminergic regulation of prepulse inhibition in rats: evidence for genetic, but not environmental determinants.

Authors:  N R Swerdlow; A Platten; Y K Kim; I Gaudet; J Shoemaker; L Pitcher; P Auerbach
Journal:  Pharmacol Biochem Behav       Date:  2001 Oct-Nov       Impact factor: 3.533

Review 6.  Behavioral approaches to the functional assessment of NMDA-mediated neural transmission in intact mice.

Authors:  S I Deutsch; R B Rosse; J Mastropaolo
Journal:  Clin Neuropharmacol       Date:  1997-10       Impact factor: 1.592

7.  A D2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia.

Authors:  R Y Peng; R S Mansbach; D L Braff; M A Geyer
Journal:  Neuropsychopharmacology       Date:  1990-06       Impact factor: 7.853

8.  Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol.

Authors:  Erica Duncan; Sandor Szilagyi; Marion Schwartz; Alena Kunzova; Shobhit Negi; Toby Efferen; Eric Peselow; Subhajit Chakravorty; Myrsini Stephanides; James Harmon; Dragana Bugarski-Kirola; Stephen Gonzenbach; John Rotrosen
Journal:  Psychiatry Res       Date:  2003-08-30       Impact factor: 3.222

9.  Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial.

Authors:  Jonathan K Wynn; Michael F Green; Joyce Sprock; Gregory A Light; Clifford Widmark; Christopher Reist; Stephen Erhart; Stephen R Marder; Jim Mintz; David L Braff
Journal:  Schizophr Res       Date:  2007-07-26       Impact factor: 4.939

Review 10.  Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings.

Authors:  G W Dalack; D J Healy; J H Meador-Woodruff
Journal:  Am J Psychiatry       Date:  1998-11       Impact factor: 18.112

View more
  2 in total

Review 1.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

2.  The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat.

Authors:  Hugo A Tejeda; Vladimir I Chefer; Agustin Zapata; Toni S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.